Trimethoprim-Sulfamethoxazole (Bactrim DS) for MRSA Cellulitis
For outpatient MRSA cellulitis, prescribe Bactrim DS (trimethoprim 160 mg/sulfamethoxazole 800 mg) 1-2 tablets twice daily for 5-10 days, with duration individualized based on clinical response.
Dosing Recommendations
Standard Dosing
The IDSA guidelines recommend TMP-SMX as a first-line oral option for empirical coverage of community-associated MRSA in outpatients with skin and soft tissue infections 1. While the guidelines don't specify exact dosing, the FDA label indicates standard dosing for various infections 2.
For MRSA cellulitis specifically:
- Dose: 1-2 Bactrim DS tablets (160/800 mg) twice daily
- Frequency: Every 12 hours
- Duration: 5-10 days based on clinical response 1
Evidence on Dose Selection
Research directly comparing standard dose (160/800 mg twice daily) versus high dose (320/1,600 mg twice daily) for MRSA skin infections found no significant difference in clinical resolution rates (73% vs 75%, p=0.79) 3. This suggests the standard dose is adequate for uncomplicated cellulitis.
However, for purulent cellulitis (cellulitis with drainage but no drainable abscess), empirical MRSA coverage is strongly recommended, while for nonpurulent cellulitis, MRSA coverage should be added only if the patient fails beta-lactam therapy or has systemic toxicity 1.
Duration Guidelines
The IDSA guidelines are explicit:
Duration should be adjusted based on:
- Speed of clinical improvement
- Resolution of erythema and warmth
- Absence of fever
- Decreasing pain and swelling
Important Clinical Considerations
When TMP-SMX is Appropriate
TMP-SMX is recommended for:
- Purulent cellulitis (cellulitis with purulent drainage, no drainable abscess) - use as monotherapy 1
- Nonpurulent cellulitis that fails beta-lactam therapy 1
- Nonpurulent cellulitis with systemic toxicity where MRSA is suspected 1
Critical Limitation
TMP-SMX does NOT cover beta-hemolytic streptococci, which are common causes of nonpurulent cellulitis. For nonpurulent cellulitis where you want to cover both streptococci and MRSA, combine TMP-SMX with a beta-lactam (e.g., amoxicillin or cephalexin) 1.
Contraindications and Warnings
- Do not use in infants <2 months of age 2
- Avoid in third trimester pregnancy (Category C/D) 1, 2
- Use caution in elderly patients, especially those on ACE inhibitors or with renal insufficiency due to hyperkalemia risk 1
- Monitor for severe skin reactions and bone marrow suppression in elderly 2
Efficacy Data
Real-world effectiveness studies support TMP-SMX for MRSA cellulitis:
- One retrospective study showed 91% treatment success with TMP-SMX versus 74% with cephalexin in a high MRSA-prevalence area 4
- Treatment with MRSA-active antibiotics reduced failure risk significantly (adjusted OR 4.22 for non-MRSA-active therapy) 4
However, a critical caveat: For severe MRSA infections including bacteremia, TMP-SMX failed to demonstrate non-inferiority to vancomycin and was associated with higher treatment failure rates 5. This reinforces that TMP-SMX is appropriate for uncomplicated outpatient cellulitis only, not severe or invasive infections.
Practical Algorithm
- Purulent cellulitis → TMP-SMX 1-2 DS tablets twice daily × 5-10 days
- Nonpurulent cellulitis, first presentation → Beta-lactam (cephalexin) first; add TMP-SMX only if failure or systemic toxicity
- Nonpurulent cellulitis requiring MRSA coverage → TMP-SMX 1-2 DS tablets twice daily PLUS amoxicillin 500 mg three times daily × 5-10 days
- Severe cellulitis or systemic illness → Hospitalize for IV vancomycin, not oral TMP-SMX
The standard dose (1-2 DS tablets twice daily) is sufficient for most cases, with 7-10 days being the typical duration for adequate clinical response.